EPCAM and breast carcinoma: Importantly, EpCAMlow, CK+ CTCs identified after size-based separation of EpCAM-depleted blood samples did not correlate with clinical outcomes in metastatic non-small cell lung, prostate, and breast cancer [27, 28].